Hilda Brito, MD
Pediatrics · Miami, FLNPI 1912063777
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by GSK at 38.1% of the total. Reporting peaked in 2024 at $419 and has fallen 57.1% since, to $180 in 2025. Among pediatrics clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$679
- Exact Sciences$235
- AstraZeneca$187
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
- Novo Nordisk$80
- Amarin Pharma, Inc.$76
- plus $342 from 13 others
Across 52 payments — averaging $2967.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$61K
- Pfizer$46K
- Amgen$45K
- Teva Pharmaceuticals USA, Inc.$3K
What the payments were for
- Food & beverage$1,782100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $679 |
| Exact Sciences | 11 | $235 |
| AstraZeneca | 8 | $187 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $183 |
| Novo Nordisk | 4 | $80 |
| Amarin Pharma, Inc. | 4 | $76 |
| Boehringer Ingelheim | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Cranial Technologies, Inc | 2 | $32 |
| Bayer | 1 | $25 |
| Evoke Pharma, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Novartis | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,782 in reported general payments places this provider in the 90th percentile of 3,964 pediatrics providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $29,640 |
| EliquisApixaban | 42 | $23,692 |
| OzempicSemaglutide | 19 | $19,545 |
| JanuviaSitagliptin Phosphate | 32 | $18,474 |
| EntrestoSacubitril/Valsartan | 12 | $9,353 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $7,838 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $5,765 |
| Omega-3 Acid Ethyl Esters | 121 | $5,402 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 116 | $5,342 |
| Candesartan Cilexetil | 57 | $4,418 |
| VascepaIcosapent Ethyl | 17 | $3,465 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,570 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,498 |
| Levemir FlexpenInsulin Detemir | 13 | $1,756 |
| Diclofenac Sodium | 103 | $1,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $679 | $29,64047 claims |
| Novo NordiskOzempic | $80 | $19,54519 claims |
| NovartisEntresto | $18 | $9,35312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,964 pediatrics providers in Florida.
Other pediatrics in Miami
- Patricia DeanMiami$92K
- Sofia MirandaMiami$67K
- Jose HerreraMiami$61K
- Joanna DavisMiami$59K
- Andrew ColinMiami$32K
- Luis BlancoMiami$13K
- Annette CaraviaMiami$9K
- Daneb GonzalezMiami$8K
- Aileen RodriguezMiami$7K
- Johana MayorMiami$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.